Back to Search
Start Over
Pharmacologic management of anorexia/cachexia.
- Source :
-
Seminars in oncology [Semin Oncol] 1998 Apr; Vol. 25 (2 Suppl 6), pp. 35-44. - Publication Year :
- 1998
-
Abstract
- Anorexia is a symptom seen in the majority of patients with cancer or the acquired immunodeficiency syndrome (AIDS) who experience involuntary weight loss. It is frequently not seen as a symptom requiring management in the same proactive manner as pain, nausea, or constipation. Progressive inanition or wasting is a fundamental component of the complex phenomenon known as the anorexia/cachexia syndrome (ACS) of malignancy or AIDS. Weight loss can be seen in the full spectrum of patient care settings: as a presenting complaint, defining condition, treatment-related toxicity, or as a hallmark of impending death. Primary pharmacologic management of ACS includes use of orexigenic agents (appetite stimulants), anticatabolic agents (antimetabolic and anticytokine), and anabolic agents (primarily hormonal). In addition to these specific categories of pharmacologic intervention, broad aspects of symptom management need to be addressed and are complementary. The available literature evaluating pharmacologic management of ACS in both malignancy and AIDS is reviewed.
- Subjects :
- Acquired Immunodeficiency Syndrome physiopathology
Anabolic Agents therapeutic use
Anorexia drug therapy
Anorexia etiology
Cachexia drug therapy
Cachexia etiology
Glucocorticoids therapeutic use
Growth Hormone therapeutic use
Humans
Neoplasms physiopathology
Progesterone Congeners therapeutic use
Serotonin Agents therapeutic use
Wasting Syndrome etiology
Xanthines
Appetite Stimulants therapeutic use
Wasting Syndrome drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 0093-7754
- Volume :
- 25
- Issue :
- 2 Suppl 6
- Database :
- MEDLINE
- Journal :
- Seminars in oncology
- Publication Type :
- Academic Journal
- Accession number :
- 9625382